Provided by Tiger Fintech (Singapore) Pte. Ltd.

Petra Acquisition Inc

0.5700
0.0000
Volume:- -
Turnover:2.04K
Market Cap:- -
PE:- -
High:0.5700
Open:0.5700
Low:0.5700
Close:0.5700
Loading ...

Petra Acquisition, Inc. Announces Share Redemption Backstop and Forward Purchase Agreements in Connection with Revelation Biosciences, Inc. Business Combination

GlobeNewswire
·
22 Dec 2021

Petra Acquisition, Inc. Announces Special Meeting of Stockholders to Approve Business Combination with Revelation Biosciences, Inc.

GlobeNewswire
·
17 Dec 2021

Revelation Biosciences Inc. Appoints Joseph A. Bellanti, M.D. to Scientific Advisory Board

GlobeNewswire
·
07 Dec 2021

Revelation Biosciences Inc. Announces Initiation of a Phase 2b Study to Assess Efficacy of Intranasal REVTx-99 for The Prevention of H3N2 Influenza

GlobeNewswire
·
02 Dec 2021

Revelation Biosciences Inc. Announces Creation and Appointments to Scientific Advisory Board

GlobeNewswire
·
29 Nov 2021

Revelation Biosciences Inc. Announces Initiation of a Phase 1b Clinical Study of REVTx-99 for the Experimental Treatment of Allergic Rhinitis and Chronic Nasal Congestion

GlobeNewswire
·
15 Nov 2021

Revelation Biosciences Inc. Engages Partnering Advisor, MedWorld Advisors, to Optimize Value of the Company’s Diagnostic Tool, REVID™

GlobeNewswire
·
01 Nov 2021

Revelation Biosciences Inc. Engages Destum Partners Inc. to Identify Strategic Partners for REVTx-99 (Ex-US) and REVTx-200 (Worldwide)

GlobeNewswire
·
26 Oct 2021

Revelation Biosciences Inc. Receives Approval to Begin a Phase 1b Clinical Study of REVTx-99 as an Experimental Treatment for Allergic Rhinitis and Chronic Nasal Congestion

GlobeNewswire
·
04 Oct 2021

Revelation Biosciences Inc. Receives Approval to Initiate Phase 2b Viral Challenge Study of REVTx 99, an Experimental Prophylactic Treatment for the Prevention of Respiratory Viral Infections

GlobeNewswire
·
28 Sep 2021